8-Substituted 3,4-dihydroquinolinones as a novel scaffold for atypical antipsychotic activity

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 20, 2005, Pages 4560-4563

  Singer, Jamie M ^a   Barr, Bridget M ^a   Coughenour, Linda L ^a   Gregory, Tracy F ^a   Walters, Michael A ^a  

^a PFIZER INC   (United States)

Author keywords

Atypical Antipsychotics; Dopamine; Serotonin

Indexed keywords

3,4 DIHYDROQUINOLINONE DERIVATIVE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; QUINOLONE DERIVATIVE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; QUINOLONES; SCHIZOPHRENIA;

EID: 24344506610     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.06.097     Document Type: Article

References (14)

1. WHO Fact Sheet Number 265; The World Health Organization: Geneva, Switzerland, 2001.
2. P. Seeman, M. Chau-Wong, J. Tedesco, and K. Wong Proc. Natl. Acad. Sci. U.S.A. 11 1975 4376
3. Martin, A. R. In Burger's Medicinal Chemistry and Drug Discovery, 5th ed.; Wolff, M. E., Ed.; Wiley-Interscience: New York, 1997; Vol. 5, p 195.
4. H.Y. Meltzer, S. Matsubara, and J. Lee J. Pharm. Exp. Ther. 251 1989 238
5. D.G. Cunningham Owens Drugs 51 1996 895
6. D.A. Wirshing, W.C. Wirshing, L. Kysar, M. Berisford, D. Goldstein, M.A. Pashdag, J. Mintz, and S. Marder J. Clin. Psychiatry 60 1999 358
7. D.G. Cunningham Owens Drugs 51 1996 895
8. D.A. Wirshing, W.C. Wirshing, L. Kysar, M. Berisford, D. Goldstein, M.A. Pashdag, J. Mintz, and S. Marder J. Clin. Psychiatry 60 1999 358
9. B. Green Curr. Med. Res. Opin. 15 1999 79
10. Davis, J. M.; Gregory, T. F.; Walters, M. A. PCT Int. Appl. WO 2004/029048; Chem. Abstr. 2004, 140, 321381.
11. Lowe III, J. A.; Nagel, A. A. U.S. Patent 4,831,031, 1988; Chem. Abstr. 1988, 111, 153842.
12. i affinity constants using the Cheng-Prusoff equation.
13. Compounds 4b and 4c were determined to be active in the d-amphetamine-stimulated locomotor activity (LMA) in vivo model.
14. None of the compounds tested from this series produced a minimally effective dose (MED) below 30 mg/kg in an in vivo catalepsy test.